Provided by Tiger Trade Technology Pte. Ltd.

Camp4 Therapeutics Corp.

4.34
0.0000
Volume:30.31K
Turnover:132.66K
Market Cap:272.35M
PE:-1.95
High:4.54
Open:4.46
Low:4.31
Close:4.34
52wk High:7.75
52wk Low:2.20
Shares:62.75M
Float Shares:38.46M
Volume Ratio:0.25
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2250
EPS(LYR):-2.6500
ROE:-545.85%
ROA:-45.25%
PB:-393.00
PE(LYR):-1.64

Loading ...

Chardan Initiates Camp4 Therapeutics at Buy With $6.50 Price Target

MT Newswires Live
·
Jun 10

Camp4 Therapeutics initiated with a Buy at Chardan

TIPRANKS
·
Jun 10

U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle

Reuters
·
Jun 10

CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital

TIPRANKS
·
Jun 10

Camp4 Therapeutics Corp : Chardan Capital Markets Initiates Coverage With Buy Rating; Target Price $6.5

THOMSON REUTERS
·
Jun 10

U.S. big tech holds 85% of Canadian cloud market, report says ahead of AI strategy

Bloomberg
·
Jun 02

Camp4 Therapeutics grants inducement option for 5,000 shares at $4.31 exercise price

Reuters
·
May 22

Camp4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 22

CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

TIPRANKS
·
May 14

CAMP4 Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Piper Sandler Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
May 08

Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY), Omada Health, Inc. (OMDA) and CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
May 08

CAMP4 Therapeutics Corp expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 08

CAMP4 Therapeutics Q1 profit misses estimates, net loss widens

Reuters
·
May 08

Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate

Benzinga Earnings
·
May 08

Camp4 Q1 FY26 net loss widens to $18.3 million

Reuters
·
May 08

Camp4 Therapeutics Corp Q1 Income From Operations USD -13.071 Million

THOMSON REUTERS
·
May 08

Camp4 expects SYNGAP1 therapy CMP-002 to enter Phase 1/2 trial in H2 2026

Reuters
·
Apr 28

Fulcrum Therapeutics Inc - on April 23, Terminated License Agreement Dated July 5, 2023 With Camp4 - SEC Filing

THOMSON REUTERS
·
Apr 27

Camp4 Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 23